ResMed Stock Forecast

Stock Price Forecast

According to 19 analysts polled by S&P Global, ResMed stock has a consensus rating of "Buy" and an average price target of $245.5. The average 1-year stock price forecast is 2.15% higher than the current stock price, while the lowest is $175 (-27.18%) and the highest is $320 (+33.15%).

Price Target: $245.5 (+2.15%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$175	$245.5	$235	$320
Change	-27.18%	+2.15%	-2.22%	+33.15%

Analyst Ratings

The average analyst rating for ResMed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	8	7	8	8	6	6
Buy	3	3	2	1	1	1
Hold	7	7	7	8	10	11
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	1
Total	19	18	18	18	18	19

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jackson Philips Rothschild & Co Redburn No rating	Rothschild & Co Redburn	Hold Initiates $230	Hold	Initiates	$230	-4.30%	Aug 19, 2026
Anthony Petrone Mizuho Securities	Mizuho Securities	Buy Maintains $220 → $235	Buy	Maintains	$220 → $235	-2.22%	Aug 12, 2026
Unknown Analyst Oppenheimer No rating	Oppenheimer	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Aug 8, 2026
Adam Maeder Piper Sandler	Piper Sandler	Hold Maintains $225	Hold	Maintains	$225	-6.38%	Aug 7, 2026
David Rescott Robert W. Baird	Robert W. Baird	Hold Maintains $217 → $213	Hold	Maintains	$217 → $213	-11.37%	Aug 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

5.82B

from 5.65B

2.91%

from 5.65B

Revenue Next Year

6.20B

from 5.82B

6.54%

from 5.82B

EPS This Year

12.09

from 11.17

8.20%

from 11.17

EPS Next Year

13.22

from 12.09

9.36%

from 12.09

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Jun 30, 2022	Jun 30, 2023	Jun 30, 2024	Jun 30, 2025	Jun 30, 2026	Jun 30, 2027
Revenue	3.58B	4.22B	4.69B	5.15B	5.65B	5.82B
Revenue Growth	11.93%	18.02%	10.95%	9.84%	9.85%	2.91%
Gross Profit	2.06B	2.39B	2.69B	3.09B	3.48B	3.63B
Gross Margin	57.68%	56.50%	57.38%	59.99%	61.62%	62.40%
Operating Income	1.00B	1.15B	1.38B	1.69B	1.92B	2.10B
Net Income	779.44M	897.56M	1.02B	1.40B	1.52B	1.63B
EPS	-	-	-	-	11.17	12.09
EPS Growth	-	-	-	-	16.96%	8.20%
Forward PE	34.10	30.82	22.86	25.32	16.42	19.89
Dividend / Share	1.68	1.76	1.92	2.12	2.40	2.66
Dividend Growth	5.66%	4.76%	9.09%	10.42%	13.21%	10.74%
Free Cash Flow	127.68M	400.59M	1.18B	1.21B	939.25M	1.64B
No. Analysts	-	-	-	-	-	28

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2027	2028	2029
High	6.0B
Avg	5.8B
Low	5.8B

Revenue Growth

Chart

Revenue Growth	2027	2028	2029
High	6.6%
Avg	2.9%
Low	1.9%

EPS Forecast

Chart

EPS	2027	2028	2029
High	12.17
Avg	12.09
Low	11.82

EPS Growth

Chart

EPS Growth	2027	2028	2029
High	9.0%
Avg	8.2%
Low	5.8%